SNTI Stock UPDATES Senesco Technologies Inc (SNTI) 1.6400 09/03/2014

New Post Public Reply Private Reply Replies (0) Message Board

Sep 3, 2014 at 1:40 PM

Senesco Technologies Inc (SNTI) 1.6400 $SNTI

Senesco concludes patient admission in Phase 1b/2a SNS01-T Study in B-cell cancers
M2 - Mon Sep 01, 5:15AM CDT
Biotech company Senesco Technologies (OTC BB:SNTI) revealed on Friday the completion of enrollment in its ongoing Phase 1b/2a open-label, multiple-dose, dose-escalation clinical trial of SNS01-T in patients with relapsed or refractory multiple myeloma, plasma cell leukemia or B cell lymphoma.

Senesco Closes Enrollment in Its Phase 1b/2a SNS01-T Study
Business Wire - Fri Aug 29, 7:15AM CDT
Senesco Technologies, Inc. ("Senesco" or the "Company"

(OTCQB:SNTI) today announced the closing of enrollment in its ongoing Phase 1b/2a open-label, multiple-dose, dose-escalation clinical trial of SNS01-T, a first-in-class modulator of eukaryotic translation initiation factor 5A (eIF5A), in patients with relapsed or refractory multiple myeloma, plasma cell leukemia or B cell lymphoma.

Senesco names Ronald A. Martell as new CEO
M2 - Thu Jun 26, 4:54AM CDT
Biotech company Senesco Technologies (OTC BB:SNTI) revealed on Wednesday the election of Ronald A. Martell as chief executive officer at the 2014 BIO International Convention in San Diego.

Senesco Presents Company Update at 2014 BIO International Convention
Business Wire - Wed Jun 25, 1:05PM CDT
Senesco Technologies, Inc. ("Senesco" or the "Company"

(OTCQB:SNTI) provided an overview of the company's current research and development status at the 2014 BIO International Convention in San Diego. Acting CEO, Vaughn V. Smider, M.D., Ph.D., presented the update, including the announcement of the completion of the administrative and financial integration of Fabrus with Senesco. The presentation will also be released in an 8-K filing and can be accessed via the company's website.

Senesco Technologies, Inc. - "Reconsidering the Entire Cancer Treatment Approach"
ACCESSWIRE - Tue Apr 01, 10:47AM CDT
BRIDGEWATER, NJ / ACCESSWIRE / April 1, 2014 / Senesco Technologies, Inc. (OTCQB: SNTI) today published a new blog post on The Chairman's Blog, written by the Company's President and CEO, Dr. Leslie J. Browne. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

Senesco Opens Two New Clinical Trial Sites and Initiates Treatment of the First Patient in South Africa
Business Wire - Wed Mar 12, 7:15AM CDT
Senesco Technologies, Inc. ("Senesco" or the "Company"

(OTCQB:SNTI) reported the opening of two new sites in the Republic of South Africa at Pretoria East Hospital and Groote Schuur Hospital in Cape Town. Treatment of the first patient in South Africa has been initiated in Senesco's Phase 1b/2a clinical study of its product candidate, SNS01-T.

Senesco pays off line of credit held by JMP Securities
M2 - Tue Mar 11, 9:34AM CDT
Senesco Technologies Inc (OTCBB:SNTI), a clinical-stage biotech company specializing in cancer therapeutics, announced on Monday that is has paid in full and cancelled the line of credit held by JMP Securities.

Senesco Pays Off Line of Credit
Business Wire - Mon Mar 10, 7:15AM CDT
Senesco Technologies, Inc. ("Senesco" or the "Company"

(OTCQB: SNTI) announces that is has paid in full and canceled the line of credit held by JMP Securities (the "Line of Credit"

.

Dean Foods Reports Fourth Quarter And Full Year 2013 Results
PR Newswire - Tue Feb 11, 7:00AM CST
Dean Foods Company (NYSE: DF) today announced that the Company earned $8.58 per diluted share for the full year 2013, as compared to $1.70 per diluted share for the full year 2012. Full year 2013 reported results include the gain on disposition of WhiteWave common stock of $416 million, the gain on sale of Morningstar of $492 million (net of tax) and other one-time or non-recurring items, as more fully described in the attached tables. On an adjusted basis, the Company earned $0.86 per diluted share for the full year 2013, compared to $0.77 for the full year 2012.

Senesco signs Letter of Intent to merge with Fabrus
M2 - Tue Dec 31, 3:58AM CST
Senesco Technologies Inc (OTCBB:SNTI), a clinical-stage biotech company specialising in cancer therapeutics, announced on Monday that it has agreed to terms and executed a non-binding Letter of Intent to merge with Fabrus Inc, a privately-held biotechnology company.

Senesco Technologies Reports Fiscal Year 2013 Financial Results
Business Wire - Thu Sep 12, 7:30AM CDT
Senesco Technologies, Inc. ("Senesco" or the "Company"

(OTCQB:SNTI) today announced financial results for the 12 months ended June 30, 2013 ("Fiscal 2013"

.

OTC Daily Alert Stock Watch - Senesco Technologies, Inc. (OTCQB:SNTI)
WorldStockWire - Wed Aug 07, 2:00AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com

Senesco Announces Results of Cohort 2 of its SNS01-T Phase 1b/2a Trial
Business Wire - Wed Jun 19, 7:30AM CDT
Senesco Technologies, Inc. ("Senesco" or the "Company"

(OTC QB: SNTI) reported results of cohort 2 in its Phase 1b/2a clinical study of SNS01-T.

Senesco Technologies Reports Second Quarter Fiscal 2013 Financial Results
Business Wire - Thu May 16, 7:30AM CDT
Senesco Technologies, Inc. ("Senesco" or the "Company"

(OTCQB: SNTI) today reported financial results for the third quarter of fiscal year 2013 which ended on March 31, 2013.

Senesco Technologies Inc expects USD1.255m in equity financing
M2 - Fri May 10, 12:59PM CDT
Cancer therapy company Senesco Technologies Inc (OTC BB:SNTI) revealed on Thursday the execution of a USD1.255m securities purchase agreement with certain institutional investors.

Senesco Announces Start of Cohort 3 in Phase 1b/2a Study in Multiple Myeloma and Non-Hodgkins B-Cell Lymphoma
Business Wire - Mon May 06, 7:30AM CDT
Senesco Technologies, Inc. ("Senesco" or the "Company"

(OTC QB: SNTI) reported today that the Data Review Committee (DRC) for its SNS01-T trial in multiple myeloma and non-Hodgkins B-cell lymphoma approved initiating cohort 3 and escalating the SNS01-T dose level four-fold to 0.2 mg/Kg. The DRC's review of the results of cohort 2 concluded that SNS01-T was safe and well tolerated at a dose of 0.05 mg/Kg. No drug-related serious adverse events or dose limiting toxicities were observed in either of the first two cohorts.

Senesco Announces Completion of Cohort 2 of its Phase 1b/2a Trial
Business Wire - Mon Apr 22, 7:30AM CDT
Senesco Technologies, Inc. ("Senesco" or the "Company"

(OTC QB: SNTI) reported today that it has completed cohort 2 in its Phase 1b/2a clinical study of SNS01-T.

Senesco Provides Management Update
Business Wire - Mon Apr 08, 8:15AM CDT
Senesco Technologies, Inc. ("Senesco" or the "Company"

(OTC:SNTI) today announced that Leslie J. Browne, Ph.D., the Company's President and Chief Executive Officer, is being treated for a medical condition that may limit his time to travel and attend public events. However, Dr. Browne will continue with his day-to-day duties and responsibilities as President and CEO of the Company. The Senesco Board has agreed to assist Dr. Browne with certain activities, including Harlan Waksal, M.D., Chairman of Senesco, who will take the lead on certain public activities like investor relations. The Board will continue to monitor Dr. Browne's responsibilities as his treatment progresses.

REIT Companies Join to Webcast Live for Special March 7th RetailInvestorConferences.com Event
CNW Group - Tue Mar 05, 12:14PM CST
Live, online webcasts presentations allow investors to ask questions in real-time and "chat" in virtual trade booths

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Seasonal Hiring Booms as Firms Eye Long-Term Talent

A Strategic Shift in Seasonal Hiring It ain't just about the holiday rush anymore, folks. Companies are waking up to the idea that seasonal gigs are more than a temporary Band-Aid. This year, nearly 2 out of 5 companies are planning to bring more seasonal folks into the fold compared to last year. That means a good dose of them are looking for longer-term value—like...

Banco Macro S.A. Plans $160B Share Buyback Initiative

Tapping into Share Buybacks in a Tumultuous Market Out of nowhere, Banco Macro S.A. has decided to whip up a share buyback program, a lifeline for their current market value. Let me tell you, the market's more volatile than a caffeinated squirrel these days, hitting the financial scenery harder than a hammer on a glass table. So, Banco Macro's taken a deep breath and...

Insurify's AI Gateway: A New Era in Insurance Shopping

Insurify's Game-Changing AI Agent Gateway In the insurance world, Insurify's latest move feels like a bull charging through a ticker tape parade. This Cambridge-based pioneer unveiled its AI Agent Gateway, aiming to put consumers back in the driver's seat. By connecting digital assistant agents to its platform, Insurify's making insurance shopping a bit less like pulling...

MetroScape: Local Roots Fuel Bold DFW Growth Plans

A Local Business with Big Aspirations Here's the deal, folks: Local guys Dr. Marc Nickell and Chris Brewer snatched up MetroScape Landscape like it was the last slice of grandma's pie. Why? Not just for the greenbacks—they're putting down roots in their very own backyard, the Dallas-Fort Worth area. What Does Local Really Mean? Look, it's one thing hitting up a...

Water UP! Celebrates Five Years, 61 Graduate So Far

Reflecting on Five Years of Water UP! New Jersey American Water's workforce development initiative, Water UP!, is painting a picture of success as it marks its fifth year. The program celebrated its 2026 graduating class at the Camden headquarters—a milestone with both numbers and faces as evidence of its impact. A Closer Look at the Journey It’s not just about a...

Infinite Electronics Reveals Cutting-Edge Connectivity at Electronica

Infinite Electronics Makes Waves at Electronica 2026 Let’s get down to brass tacks: Infinite Electronics is setting up one heck of a show at the electronica 2026 in Munich from November 10–13. They're not just there to give out free pens—these guys mean business with connectivity products that cover everything from drones to industrial automation. A Showcase of...

Temu Joins DBI to Boost Irish Digital Business Growth

You know it's a lively day when Temu, the big fish in the e-commerce pond, decides to dive into Ireland's digital waters by joining forces with Digital Business Ireland (DBI). Yeah, we're talking about more than just a handshake here. If you’re wondering why this matters, keep your ears open to the whispers of opportunity. Temu's addition isn't just a membership; it's a...

Nikon Unveils Game-Changing Zoom Lens for Pros

Nikon Raises the Bar with New Pro Zoom Lens Well, Nikon's done it again, folks. They've dropped the NIKKOR Z 120-300mm f/2.8 TC VR S lens, and it looks like they're giving photographers something to drool over. Now, before you start rolling your eyes, this isn't just another shiny gadget. This bad boy is lighter and faster than anything Nikon's thrown at us before, and it...

Lilly Taps AI for Alzheimer’s Research with SpeechDx

Some folks might just brush off a little forgetfulness as old age, but what if we could pinpoint Alzheimer's up front with just the way someone talks? That’s the big league play Eli Lilly's making by licensing the SpeechDx dataset from the Alzheimer's Drug Discovery Foundation (ADDF). This ain't your run-of-the-mill data—it's the largest harmonized longitudinal...

Minesto Charts Bold Tides with Dragon Farms Funding

Minesto’s making waves, folks, and it ain’t just its tech splashing around. This Swedish tidal power ace is strutting on the global stage, flexing some serious muscle with projects that mean business. From the dragon-taming Faroe Islands to the Irish coasts, they’re pushing the envelope on tidal energy, and investors might wanna take note. Dragon Power Unleashed:...